Machine Learning-Based Prediction of Escitalopram and Sertraline Side Effects With Pharmacokinetic Data in Children and Adolescents. Poweleit, EA; Vaughn, SE; Desta, Z; Dexheimer, JW; Strawn, JR; Ramsey, LB. Clinical Pharmacology and Therapeutics. 2024; 115:860-870.

Influence of CYP2D6 Metabolizer Status on Risperidone and Paliperidone Tolerability in Children and Adolescents. Kanu, AA; Johnston, MM; Poweleit, EA; Vaughn, SE; Strawn, JR; Ramsey, LB. Journal of Child and Adolescent Psychopharmacology. 2024; 34:34-41.

Escitalopram and Sertraline Population Pharmacokinetic Analysis in Pediatric Patients. Poweleit, EA; Taylor, ZL; Mizuno, T; Vaughn, SE; Desta, Z; Strawn, JR; Ramsey, LB. Clinical Pharmacokinetics. 2023; 62:1621-1637.

3.102 Pharmacogenetic Variants Differentially Impact Hyperprolactinemia in Patients Treated With Risperidone or Paliperidone. Vaughn, S; Kanu, A; Johnston, M; Poweleit, EA; Strawn, JR; Ramsey, LB. Journal of the American Academy of Child and Adolescent Psychiatry. 2022; 61:s261.

Voices from limbo: Experiences with pediatric boarding during a youth mental health crisis. Kurtz, BP; Vaughn, S. Journal of hospital medicine (Online). 2022; 17:854-855.

Pediatric Psychopharmacology for Depressive and Anxiety Disorders. Strawn, JR; Vaughn, S; Ramsey, LB. Focus. 2022; 20:184-190.

The Impact of Marijuana on Antidepressant Treatment in Adolescents: Clinical and Pharmacologic Considerations. Vaughn, SE; Strawn, JR; Poweleit, EA; Sarangdhar, M; Ramsey, LB. Journal of Personalized Medicine. 2021; 11.

The need for a refined understanding of CYP2D6 in second-generation antipsychotic outcomes in children and adolescents. Rossow, KM; Vaughn, SE; Strawn, JR; Van Driest, SL; Ramsey, LB. Pharmacogenomics. 2021; 22:447-450.

Comorbidity of Bipolar and Other Psychiatric Disorders. Vaughn, SE; Strawn, JR. Bipolar Disorder. : Oxford University Press (OUP); Oxford University Press (OUP); 2020.